Smith & Nephew plc (NYSE:SNN) Shares Acquired by GAMMA Investing LLC

GAMMA Investing LLC boosted its stake in Smith & Nephew plc (NYSE:SNN - Free Report) by 3,372.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 103,295 shares of the medical equipment provider's stock after purchasing an additional 100,320 shares during the quarter. GAMMA Investing LLC's holdings in Smith & Nephew were worth $2,930,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the stock. Versant Capital Management Inc increased its holdings in shares of Smith & Nephew by 1,970.2% in the first quarter. Versant Capital Management Inc now owns 5,217 shares of the medical equipment provider's stock worth $148,000 after purchasing an additional 4,965 shares during the period. Marotta Asset Management boosted its holdings in shares of Smith & Nephew by 6.4% during the first quarter. Marotta Asset Management now owns 12,613 shares of the medical equipment provider's stock worth $393,000 after purchasing an additional 764 shares during the period. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Smith & Nephew in the 4th quarter worth approximately $857,000. Vident Advisory LLC raised its stake in Smith & Nephew by 158.8% in the fourth quarter. Vident Advisory LLC now owns 21,564 shares of the medical equipment provider's stock worth $530,000 after buying an additional 13,232 shares in the last quarter. Finally, Wexford Capital LP purchased a new position in Smith & Nephew during the fourth quarter valued at $541,000. Hedge funds and other institutional investors own 25.64% of the company's stock.

Smith & Nephew Stock Down 2.6%

Smith & Nephew stock traded down $0.79 during midday trading on Friday, hitting $29.33. 838,174 shares of the company's stock were exchanged, compared to its average volume of 800,171. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51. The firm has a 50-day moving average of $27.95 and a two-hundred day moving average of $26.85. Smith & Nephew plc has a 12 month low of $23.69 and a 12 month high of $31.72. The company has a market cap of $12.84 billion, a PE ratio of 13.58, a P/E/G ratio of 1.26 and a beta of 0.68.

Analyst Upgrades and Downgrades

SNN has been the subject of several recent research reports. UBS Group lowered shares of Smith & Nephew from a "buy" rating to a "neutral" rating in a report on Wednesday, March 12th. Hsbc Global Res cut Smith & Nephew from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Wall Street Zen raised Smith & Nephew from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, February 26th. HSBC lowered Smith & Nephew from a "buy" rating to a "hold" rating in a research report on Friday, April 25th. Finally, Canaccord Genuity Group increased their price objective on shares of Smith & Nephew from $27.00 to $28.00 and gave the company a "hold" rating in a research report on Thursday, May 1st. Six equities research analysts have rated the stock with a hold rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $28.00.

About Smith & Nephew

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.